GNLX Insider Transactions — Page 2
146 retained open-market purchase and sale rows from SEC Forms 3, 4 and 5, newest first. This page shows rows 101–146; provenance stays internal.
| Insider profile | Role | Date | Transaction | Shares | Price |
|---|---|---|---|---|---|
| Yu Yong | VP, Clinical Trial Operations | 2023-09-26 | Sale | 2,203.0 | $24.46 |
| Yu Yong | VP, Clinical Trial Operations | 2023-09-26 | Sale | 1,114.0 | $23.51 |
| Yu Yong | VP, Clinical Trial Operations | 2023-09-26 | Sale | 1,883.0 | $22.54 |
| Szalay Aladar | TenPercentOwner | 2023-09-25 | Sale | 1,100.0 | $27.81 |
| Szalay Aladar | TenPercentOwner | 2023-09-25 | Sale | 1,900.0 | $26.6 |
| Szalay Aladar | TenPercentOwner | 2023-09-25 | Sale | 5,511.0 | $25.75 |
| Szalay Aladar | TenPercentOwner | 2023-09-25 | Sale | 3,947.0 | $24.82 |
| Szalay Aladar | TenPercentOwner | 2023-09-22 | Sale | 4,621.0 | $27.76 |
| Szalay Aladar | TenPercentOwner | 2023-09-22 | Sale | 4,421.0 | $26.88 |
| Szalay Aladar | TenPercentOwner | 2023-09-21 | Sale | 4,678.0 | $28.82 |
| Szalay Aladar | TenPercentOwner | 2023-09-21 | Sale | 2,871.0 | $27.89 |
| Yu Yong | VP, Clinical Trial Operations | 2023-09-20 | Sale | 6,000.0 | $27.96 |
| Ryder Sean | General Counsel | 2023-09-20 | Sale | 10,000.0 | $30.0 |
| Szalay Aladar | TenPercentOwner | 2023-09-19 | Sale | 8,247.0 | $27.16 |
| Szalay Aladar | TenPercentOwner | 2023-09-19 | Sale | 23,920.0 | $26.21 |
| Szalay Aladar | TenPercentOwner | 2023-09-18 | Sale | 2,927.0 | $24.17 |
| Szalay Aladar | TenPercentOwner | 2023-09-18 | Sale | 27,365.0 | $23.2 |
| Thomas John | Director | 2023-09-18 | Sale | 3,334.0 | $24.99 |
| Yu Yong | VP, Clinical Trial Operations | 2023-09-15 | Sale | 4,675.0 | $22.29 |
| Yu Yong | VP, Clinical Trial Operations | 2023-09-15 | Sale | 5,725.0 | $21.56 |
| Thomas John | Director | 2023-09-15 | Sale | 1,088.0 | $22.38 |
| Thomas John | Director | 2023-09-15 | Sale | 2,245.0 | $21.67 |
| Szalay Aladar | TenPercentOwner | 2023-09-14 | Sale | 13,871.0 | $22.31 |
| Szalay Aladar | TenPercentOwner | 2023-09-14 | Sale | 11,405.0 | $21.77 |
| Yu Yong | VP, Clinical Trial Operations | 2023-09-13 | Sale | 29,800.0 | $21.14 |
| Szalay Aladar | TenPercentOwner | 2023-09-13 | Sale | 3,315.0 | $22.31 |
| Szalay Aladar | TenPercentOwner | 2023-09-13 | Sale | 15,717.0 | $21.26 |
| Smither John W | Director | 2023-09-13 | Sale | 900.0 | $20.78 |
| Szalay Aladar | TenPercentOwner | 2023-09-12 | Sale | 13,727.0 | $22.51 |
| Szalay Aladar | TenPercentOwner | 2023-09-12 | Sale | 6,538.0 | $21.75 |
| Szalay Aladar | TenPercentOwner | 2023-09-11 | Sale | 23,020.0 | $22.55 |
| Szalay Aladar | TenPercentOwner | 2023-09-11 | Sale | 9,331.0 | $21.39 |
| Szalay Aladar | TenPercentOwner | 2023-09-08 | Sale | 2,636.0 | $24.19 |
| Szalay Aladar | TenPercentOwner | 2023-09-08 | Sale | 8,523.0 | $23.49 |
| Szalay Aladar | TenPercentOwner | 2023-09-08 | Sale | 13,672.0 | $22.78 |
| Szalay Aladar | TenPercentOwner | 2023-09-07 | Sale | 2,508.0 | $25.34 |
| Szalay Aladar | TenPercentOwner | 2023-09-07 | Sale | 9,938.0 | $24.12 |
| Yu Yong | VP, Clinical Trial Operations | 2023-08-30 | Sale | 19,800.0 | $24.7 |
| Jewett Caroline | Head of Quality | 2023-08-18 | Sale | 515.0 | $23.73 |
| Smalling Ralph | Head of Regulatory | 2023-08-18 | Sale | 935.0 | $23.73 |
| Samuelson Doug | Chief Financial Officer | 2023-08-18 | Sale | 1,297.0 | $23.73 |
| Ryder Sean | General Counsel | 2023-08-18 | Sale | 328.0 | $23.73 |
| Cappello Joseph | VP, Pharmaceutical Development | 2023-08-18 | Sale | 3,265.0 | $23.73 |
| Yu Yong | VP, Clinical Trial Operations | 2023-08-18 | Sale | 3,265.0 | $23.73 |
| Zindrick Thomas | President and CEO | 2023-08-18 | Sale | 8,349.0 | $23.73 |
| Zhang Qian | Associate VP, Research | 2023-01-26 | Purchase | 200.0 | $6.25 |